Exodus Point Capital Management, LP Igm Biosciences, Inc. Transaction History

Exodus Point Capital Management, LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$6.51 - $11.47 $333,181 - $587,034	51,180 Added 251.83%	71,503 $491,000
Q1 2024 May 14, 2024	SELL	$8.68 - $17.36 $3.76 Million - $7.53 Million	-433,575 Reduced 95.52%	20,323 $196,000
Q3 2023 Nov 09, 2023	BUY	$6.66 - $10.64 $3.02 Million - $4.83 Million	453,898 New	453,898 $3.79 Million
Q1 2023 May 11, 2023	BUY	$13.74 - $25.76 $172,711 - $323,803	12,570 Added 26.7%	59,650 $820,000
Q4 2022 Feb 13, 2023	BUY	$15.45 - $26.02 $333,642 - $561,901	21,595 Added 84.74%	47,080 $801,000
Q3 2022 Nov 10, 2022	BUY	$15.42 - $27.01 $392,978 - $688,349	25,485 New	25,485 $580,000
Q2 2022 Aug 19, 2022	SELL	$13.27 - $25.5 $142,360 - $273,564	-10,728 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$13.42 - $29.73 $22,787 - $50,481	1,698 Added 18.8%	10,728 $287,000
Q4 2021 Feb 11, 2022	BUY	$27.59 - $66.39 $107,683 - $259,120	3,903 Added 76.13%	9,030 $265,000
Q3 2021 Nov 15, 2021	SELL	$65.76 - $90.65 $109,556 - $151,022	-1,666 Reduced 24.53%	5,127 $337,000
Q2 2021 Aug 16, 2021	BUY	$57.98 - $96.6 $22,670 - $37,770	391 Added 6.11%	6,793 $565,000
Q1 2021 May 17, 2021	BUY	$71.56 - $121.23 $458,127 - $776,114	6,402 New	6,402 $491,000
Q4 2020 Feb 16, 2021	SELL	$47.41 - $115.03 $203,625 - $494,053	-4,295 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$43.0 - $84.01 $184,685 - $360,822	4,295 New	4,295 $317,000
Q2 2020 Aug 14, 2020	SELL	$51.3 - $75.21 $1.53 Million - $2.24 Million	-29,834 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$31.51 - $73.75 $940,069 - $2.2 Million	29,834 New	29,834 $1.68 Million

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $200M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.